MoFo News Item

Morrison & Foerster Named Firm of the Year in Six Practice Areas by China Business Law Journal

24 May 2021

China Business Law Journal has named Morrison & Foerster Firm of the Year in the six practice areas listed below in its 2021 China Business Law Awards.

  • Fintech & blockchain 金融科技及区块链
  • Healthcare, pharma, & life sciences 医疗、制药及生命科学
  • M&A (inbound & domestic) 境内并购
  • Media, entertainment, & sports 传媒、娱乐及体育
  • Real estate & REIT 房地产投资及REIT基金
  • Technology & telecom 信息科技及电信

The China Business Law Awards are based on hundreds of nominations received from China-focused corporate counsel and legal professionals around the world. In determining the winners, the nominations (and the justifications provided for each nomination) were considered carefully in combination with other factors, such as each firm’s landmark deals, cases, and other notable achievements over the past year. You can view the list of winners by visiting the website.

During the past year, Morrison & Foerster handled a number of significant transactional and contentious matters for our clients, including:

  • SoftBank Group Corp. and SoftBank Vision Fund in the US$40 billion sale of UK-headquartered multinational semiconductor and software design company Arm Limited to U.S. chip company NVIDIA (NASDAQ: NVDA).
  • A leading institutional investor in connection with Grab’s proposed US$39.6 billion merger with a special purpose acquisition company.
  • Ally Bridge Group in connection with more than US$1 billion in financing of various growth, late stage, and public life sciences companies across the United States and Europe, including Atea Pharmaceuticals, Goldfinch Biopharma, and Pulmonx.
  • A wholly owned subsidiary of Greenland Hong Kong in its RMB7.26 billion acquisition of Guangzhou Greenland Real Estate Development.
  • Ping An Insurance (Group) Company of China Ltd. in its capital and strategic alliance with Shionogi & Co., Ltd. with a total value of US$780 million, which includes (i) subscription of a 2.05% voting stake in Shionogi and (ii) establishment of joint ventures in Shanghai and Hong Kong. Shionogi is a leading research-driven pharmaceutical company headquartered in Japan.
  • The joint sponsors, CLSA Capital Markets Limited and Huatai Financial Holdings (Hong Kong) Limited, and underwriters in relation to Jinke Smart Services Group Co., Ltd.’s HK$5,941.1 million IPO on the Hong Kong Stock Exchange.
  • Ascendent Capital Partners in its disposal of Etern Group Ltd., which indirectly holds 98% of the equity interest in a general hospital in Suzhou, to Hygeia, a Hong Kong-listed healthcare company, for a total consideration of RMB1,734,600,000 (approximately US$267 million).
  • Roblox in its joint venture with Tencent (Luobu) and the establishment and launch of the Roblox platform in China. The initial capitalization of the JV is US$100 million.
  • Changchun High & New Technology Industry Group Inc. in its US$28.3 million Series A investment in Brillian Pharma Inc., a pharmaceutical company focused on research and development of high-end generic medicine and modified pediatric medicine.
  • Tata Health International Holdings Limited, an online healthcare provider, in its equity fund raising of HK$74,997,000 by issuing new shares under a specific mandate.
  • Triastek, Inc., a leading pharmaceutical company specializing in 3D printing of drug products, in its co‑development agreement with Sperogenix Therapeutics Limited, a company focusing on development and commercialization of rare disease medications in China, to jointly develop 3D-printed medicines for rare diseases.
  • SoftBank Group in Hong Kong actions seeking documentary and testimonial evidence in Hong Kong and Mainland China for use in a high-profile action filed by WeWork in the Delaware Chancery Court.
  • A Chinese real estate giant in defending a Hong Kong High Court action arising out of various agreements related to a high-profile real estate development in Macau.
  • An investment management company wholly owned by a Hong Kong‑listed Chinese securities company in a high-value Hong Kong-seated HKIAC arbitration arising out of an exempted limited partnership agreement governed by Cayman Islands law.
  • A Fortune 100 life sciences company in its various internal investigations of FCPA and other compliance concerns in Mainland China, Taiwan, and South Korea.
  • A U.S.-based technology company specializing in audio, visual, and voice technologies in a potential HKIAC arbitration arising out of a patent license agreement governed by California law.
  • A NYSE-listed technology company in private antitrust litigation in China brought by a former Chinese distributor in the software market.
  • A prominent offshore investment fund and its director in connection with the ongoing international government investigations into the 1Malaysia Development Berhad scandal.
  • A major commercial bank in Mainland China/Hong Kong to evaluate enforcement risks and devise risk mitigation measures in response to expanding economic sanctions regimes targeting Mainland China/Hong Kong, including those by the United States, United Kingdom, and the European Union.
  • A major Hong Kong-based financial institution in sanctions and export control issues in connection with procuring services and technologies from Chinese companies subject to U.S. trade restrictions.
  • A major Chinese/Hong Kong investment bank to evaluate CFIUS and U.S. national security-related risks in connection with its investments in various sectors.


Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.